Top 50 Life Science Startup Investors in United States (October 2026)
For AI agents: Short investor table (Markdown), Detailed investor list (Markdown)
| Investor | Relevant Deals | Geography | Stage | Focus | Round Size |
|---|---|---|---|---|---|
|
SOSV
VC Fund
|
95 | United States, China, Canada | Seed, Convertible Note, Pre-Seed | Biotechnology, Health Care, Software | $50k–$5M |
|
SOSV SF & NY (Fka IndieBio)
VC Fund
|
53 | United States, United Kingdom, Canada | Seed, Pre-Seed, Convertible Note | Biotechnology, Health Care, Medical | $50k–$5M |
|
ARCH Venture Partners
VC Fund
|
43 | United States, China, United Kingdom | Series A, Series B, Series C | Biotechnology, Health Care, Therapeutics | $9.1M–$230M |
|
Alexandria Venture Investments
VC Fund
|
35 | United States, Canada, France | Series A, Series B, Series C | Biotechnology, Health Care, Therapeutics | $12M–$150M |
|
Alumni Ventures
VC Fund
|
27 | United States, United Kingdom, Canada | Seed, Series A, Series B | Software, Artificial Intelligence, Health Care | $850k–$75M |
|
Atlas Venture
VC Fund
|
25 | United States, United Kingdom, Canada | Series A, Series B, Seed | Biotechnology, Health Care, Therapeutics | $750k–$115M |
|
8VC
VC Fund
|
24 | United States, United Kingdom, Canada | Seed, Series A, Series B | Software, Artificial Intelligence, Health Care | $2.5M–$181M |
|
Third Rock Ventures
VC Fund
|
22 | United States, Japan, Israel | Series A, Series B, Series C | Biotechnology, Health Care, Therapeutics | $11M–$190M |
|
Northpond Ventures
VC Fund
|
21 | United States, United Kingdom, Canada | Series A, Series B, Series C | Biotechnology, Health Care, Life Science | $13M–$95M |
|
RA Capital Management
VC Fund
|
21 | United States, United Kingdom, China | Series B, Post-IPO Equity, Series A | Biotechnology, Health Care, Therapeutics | $20M–$275M |
|
OrbiMed
VC Fund
|
21 | United States, China, Israel | Series B, Series A, Series C | Biotechnology, Health Care, Pharmaceutical | $9M–$160M |
|
Andreessen Horowitz
VC Fund
|
20 | United States, United Kingdom, Canada | Series A, Seed, Series B | Software, Artificial Intelligence, Information Technology | $1.5M–$120M |
|
Gaingels
VC Fund
|
20 | United States, Canada, United Kingdom | Seed, Series A, Venture - Series Unknown | Software, Artificial Intelligence, Health Care | $72k–$35M |
|
Google Ventures
VC Fund
|
20 | United States, United Kingdom, Israel | Series A, Series B, Seed | Software, Health Care, Biotechnology | $1.1M–$121M |
|
Liquid 2 Ventures
VC Fund
|
19 | United States, Mexico, Canada | Seed, Pre-Seed, Series A | Software, Artificial Intelligence, Information Technology | $125k–$48M |
|
DCVC
VC Fund
|
16 | United States, United Kingdom, Canada | Seed, Series A, Series B | Software, Artificial Intelligence, Machine Learning | $1M–$130M |
|
Novartis Venture Fund
VC Fund
|
16 | United States, Switzerland, United Kingdom | Series B, Series A, Series C | Biotechnology, Health Care, Therapeutics | $5.1M–$107M |
|
Fifty Years
VC Fund
|
15 | United States, Germany, Canada | Seed, Series A, Pre-Seed | Biotechnology, Health Care, Artificial Intelligence | $572k–$40M |
|
Felicis
VC Fund
|
15 | United States, Canada, United Kingdom | Series A, Seed, Series B | Software, Artificial Intelligence, SaaS | $1.5M–$76M |
|
Alix Ventures
VC Fund
|
14 | United States | Seed, Series A, Pre-Seed | Health Care, Biotechnology, Life Science | $2M–$70M |
|
KdT Ventures
VC Fund
|
14 | United States, India, Canada | Seed, Series A, Series B | Biotechnology, Health Care, Medical | $2.6M–$175M |
|
Flagship Pioneering
VC Fund
|
14 | United States, Canada, United Kingdom | Series B, Series C, Series A | Biotechnology, Health Care, Medical | $6.6M–$230M |
|
Foresite Capital
VC Fund
|
14 | United States, United Kingdom, China | Series B, Series C, Series A | Biotechnology, Health Care, Medical | $17M–$270M |
|
Apple Tree Partners
VC Fund
|
14 | United States, Canada, United Kingdom | Series A, Series B, Seed | Biotechnology, Health Care, Therapeutics | $3.5M–$100M |
|
Lux Capital
VC Fund
|
14 | United States, United Kingdom, Canada | Series A, Seed, Series B | Software, Artificial Intelligence, Health Care | $1.6M–$150M |
|
TCA Venture Group
VC Fund
|
14 | United States, Canada, South Africa | Seed, Venture - Series Unknown, Convertible Note | Health Care, Software, Biotechnology | $50k–$8.5M |
|
Cormorant Asset Management
VC Fund
|
13 | United States, China, Switzerland | Series B, Series C, Series A | Biotechnology, Health Care, Medical | $16M–$150M |
|
The Column Group
VC Fund
|
13 | United States | Series A, Series B, Series C | Biotechnology, Health Care, Therapeutics | $15M–$120M |
|
General Catalyst
VC Fund
|
13 | United States, India, United Kingdom | Seed, Series A, Series B | Software, Artificial Intelligence, Health Care | $1.6M–$123M |
|
Pear VC
VC Fund
|
13 | United States, Brazil, Colombia | Seed, Pre-Seed, Series A | Software, Artificial Intelligence, Information Technology | $175k–$40M |
|
Khosla Ventures
VC Fund
|
12 | United States, United Kingdom, India | Series A, Seed, Series B | Artificial Intelligence, Software, Health Care | $1.8M–$100M |
|
Right Side Capital Management
VC Fund
|
12 | United States, Canada, United Kingdom | Pre-Seed, Convertible Note, Seed | Software, Artificial Intelligence, SaaS | $50k–$1.7M |
|
Two Sigma Ventures
VC Fund
|
12 | United States, Canada, Mexico | Series A, Seed, Series B | Software, Artificial Intelligence, Machine Learning | $1.5M–$120M |
|
MPM Capital
VC Fund
|
12 | United States, Canada, United Kingdom | Series B, Series A, Series C | Biotechnology, Health Care, Therapeutics | $10M–$116M |
|
Omega Funds
VC Fund
|
12 | United States, Switzerland, United Kingdom | Series A, Series B, Series C | Biotechnology, Health Care, Therapeutics | $14M–$208M |
|
Village Global
VC Fund
|
12 | United States, United Kingdom, India | Seed, Pre-Seed, Series A | Software, Artificial Intelligence, Financial Services | $250k–$22M |
|
Civilization Ventures
VC Fund
|
12 | United States, United Kingdom, Brazil | Seed, Series A, Series B | Biotechnology, Health Care, Medical | $1.8M–$144M |
|
F-Prime
VC Fund
|
12 | United States, China, United Kingdom | Series A, Series B, Seed | Health Care, Biotechnology, Medical | $1.6M–$112M |
|
New Enterprise Associates
VC Fund
|
12 | United States, China, India | Series A, Series B, Series C | Software, Health Care, Biotechnology | $6M–$100M |
|
Connecticut Innovations
VC Fund
|
11 | United States, Israel, Canada | Seed, Series A, Series B | Health Care, Biotechnology, Software | $150k–$75M |
|
Artis Ventures
VC Fund
|
11 | United States, United Kingdom, India | Series A, Series B, Seed | Health Care, Biotechnology, Software | $2.1M–$127M |
|
Catalio Capital Management
VC Fund
|
11 | United States, Israel, Switzerland | Series A, Series B, Series C | Biotechnology, Health Care, Medical | $9.7M–$208M |
|
SV Angel
VC Fund
|
11 | United States, Canada, United Kingdom | Seed, Series A, Series B | Software, Artificial Intelligence, Information Technology | $1M–$100M |
|
Playground Global
VC Fund
|
11 | United States, Canada, Australia | Series A, Seed, Series B | Software, Artificial Intelligence, Robotics | $2.3M–$150M |
|
iSelect Fund
VC Fund
|
11 | United States, Canada, Australia | Seed, Series A, Venture - Series Unknown | Biotechnology, Health Care, Agriculture | $500k–$41M |
|
Hatteras Venture Partners
VC Fund
|
11 | United States, Canada | Series A, Series B, Series C | Health Care, Biotechnology, Medical | $2.6M–$88M |
|
Sahsen Ventures
VC Fund
|
11 | United States, United Kingdom, China | Venture - Series Unknown, Seed | Biotechnology, Health Care, Non Profit | $1.2M–$135M |
|
Digitalis Ventures
VC Fund
|
11 | United States, United Kingdom, China | Series A, Seed, Series B | Biotechnology, Health Care, Medical | $1.5M–$150M |
|
SR One
VC Fund
|
11 | United States, United Kingdom, Canada | Series A, Series B, Series C | Biotechnology, Health Care, Therapeutics | $6M–$175M |
|
Vivo Capital
VC Fund
|
10 | United States, China, United Kingdom | Post-IPO Equity, Series B, Series C | Biotechnology, Health Care, Pharmaceutical | $28M–$180M |
| Access all 4079 investors in United States Life Science startups. | |||||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Investor list
SOSV offers pre-seed capital and follow-on financial support to startups focusing on deep technology and scientific innovation. Founders utilize purpose-built laboratory facilities and engineering spaces to accelerate product development and testing. The firm facilitates connections between entrepreneurs and a network of investors through structured matchmaking events and technology summits.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Software
- Stage:Seed, Convertible Note, Pre-Seed
- Geography: United States, China, Canada
Investor stats
- Total investments: 3729
- Round size: Seed $150k–$5M; Pre-Seed $50k–$1.6M; Convertible Note $50k–$3.6M
- Lead/follow: 37% lead, 63% follow
- Last fund: Likely still investing — raised $306M in 2023
Portfolio highlights
- Halla — Halla Intelligence is a digital solution that leverages over 100 billion shopper and product data points to recommend and promote what grocery items.
- Simply Good Jars — Simply Good Jars is a B-Corp company that delivers healthy meals in reusable + returnable packaging through use of smart refrigerated kiosks placed in offices, transit centers, universities and health-systems. Driven by purpose to change that way people think about consumption, SGJ introduces sustainable business practices into their everydayoperations with a zero-waste goal. For every jar returned back to the company for reuse, they will help feed someone in need and ensure that no packaging materials end up in landfills.
- Verdex Technologies — Verdex Technologies is an advanced materials platform technology that uses nanofibers to disrupt industries. Verdex doesn't just compete, it innovates and disrupts.
IndieBio, re-named SOSV SF and SOSV NY in 2026, are two of SOSV’s three deeply resourced facilities for deep tech founders. The third is SOSV's HAX, in Newark, NJ. SOSV is the most active deep tech venture capital firm globally.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Seed, Pre-Seed, Convertible Note
- Geography: United States, United Kingdom, Canada
Investor stats
- Total investments: 676
- Round size: Seed $250k–$5M; Pre-Seed $50k–$525k; Convertible Note $150k–$950k
- Lead/follow: 3% lead, 97% follow
Portfolio highlights
- FluoSphera — Fluosphera better predicts the effects of molecules through animal-free microphysiological systems, helping you to discover more efficient drugs with less adverse side effects.
- Giraffe Bio — Giraffe Bio uses AI and biomolecules to optimize metal extraction, increase yield, and reduce environmental impact. Revolutionizing sustainable mining technology.
- Transition Metal Solutions — Transition harnesses wild microbial communities to recover copper and other critical metals from low-grade mining resources.
ARCH Venture Partners provides seed / early stage venture capital for technology firms in information technology, life sciences, and physical sciences
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Series B, Series C
- Geography: United States, China, United Kingdom
Investor stats
- Total investments: 475
- Round size: Series A $9.1M–$213M; Series B $15M–$230M; Series C $15M–$167M
- Lead/follow: 32% lead, 68% follow
- Last fund: Likely still investing — raised $3B in 2024
Portfolio highlights
- Oratomic — Oratomic is a Pasadena-based quantum computing company building fault-tolerant quantum computers with neutral atoms.
- Synchron — The endovascular brain computer interface.
- Soufflé Therapeutics — Soufflé Therapeutics is a biotechnology company specializing in the development of nucleic acid medicines designed for precise delivery and targeting of disease-causing cells. The company's mission is to create potent, precise, and safe medicines that can be tailored for a broad range of diseases by leveraging breakthroughs in genetic medicineand drug delivery technology.
Alexandria Venture Investments is a venture capital firm that develops work in real estate technology, and healthcare sectors. The company's strategic venture capital platform is Alexandria Venture Investments. Since its inception in 1996, the company has invested in disruptive life science, agrifood tech, and technology companies that are developing transformative new modalities and platforms to meaningfully improve human health.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Series B, Series C
- Geography: United States, Canada, France
Investor stats
- Total investments: 298
- Round size: Series A $12M–$100M; Series B $25M–$150M; Series C $22M–$140M
- Lead/follow: 8% lead, 92% follow
Portfolio highlights
- Leal Therapeutics — Leal Therapeutics develops novel therapeutics for patients.
- BigHat Biosciences — We use machine learning and synthetic biology to design and engineer antibody therapeutics.
- Khartis Therapeutics — Khartis is a drug discovery company developing oral therapies for patients with immune-mediated and chronic diseases. The company focuses on discovering and developing drug candidates intended to address chronic conditions and immune-mediated diseases.
Access curated startup investment opportunities and diversified venture capital exposure designed for accredited investors.
Show more...Investment focus
- Industry: Software, Artificial Intelligence, Health Care
- Stage:Seed, Series A, Series B
- Geography: United States, United Kingdom, Canada
Investor stats
- Total investments: 2705
- Round size: Seed $850k–$9.9M; Series A $3.5M–$32M; Series B $8M–$75M
- Lead/follow: 4% lead, 96% follow
- Last fund: Likely actively investing — fresh fund, raised $90k in 2026
Portfolio highlights
- NextDroid — NextDroid - We're Doing Something Different
- Hello Patient — Healthcare AI that gets your team off the phone & in front of patients
- Alva Energy — Alva Energy is a nuclear solution based firm that aids challenges related to nuclear power offering on time delivery of nuclear megawatts.
Atlas Venture is an early-stage venture capital firm that creates and invests in biotech startup companies led by promising entrepreneurs focusing on life sciences innovation. Its seed-led venture creation strategy rigorously selects and focuses investment on compelling opportunities to build scalable businesses and realize value.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Series B, Seed
- Geography: United States, United Kingdom, Canada
Investor stats
- Total investments: 475
- Round size: Seed $750k–$25M; Series A $4M–$75M; Series B $8M–$115M
- Lead/follow: 30% lead, 70% follow
- Last fund: Likely actively investing — fresh fund, raised $400M in 2025
Portfolio highlights
- E Ink — E Ink Corp. is a supplier of electronic paper display (EPD) technologies. Products made with E Ink's electronic ink are designed to possess a paper-like high contrast appearance, ultra-low power consumption, and a thin, light form. E Ink's technology is tailored for many consumer and industrial applications including handheld devices, watches, clocks, and public information and promotional signs.
- Songbird — DropCatch.com helps you secure expiring domain names.
- Ethyreal Bio — Ethyreal Bio is an early-stage biotechnology company developing precision, mechanism-driven therapies for thyroid diseases with high unmet medical needs.
8VC focuses its investment activities on industries such as life sciences, healthcare, logistics, manufacturing, enterprise software, and defense. Its portfolio support model aids founders in scaling transformational technologies intended to create long-term economic and societal value. The firm actively finances breakthroughs ranging from medical innovations and zero-emission transit models to security compliance and infrastructure automation.
Show more...Investment focus
- Industry: Software, Artificial Intelligence, Health Care
- Stage:Seed, Series A, Series B
- Geography: United States, United Kingdom, Canada
Investor stats
- Total investments: 678
- Round size: Seed $2.5M–$13M; Series A $7.7M–$55M; Series B $17M–$181M
- Lead/follow: 32% lead, 68% follow
- Last fund: Likely actively investing — fresh fund, raised $45M in 2026
Portfolio highlights
- Harbor — Harbor is a specialized platform designed to provide insurance and risk management for the AI agentic economy. As AI agents increasingly take over autonomous decision-making tasks within enterprise environments, they introduce unique operational, security, and regulatory risks that traditional safety controls are not built to handle.
- Hello Patient — Healthcare AI that gets your team off the phone & in front of patients
- Sirona Medical — Sirona Medical is revolutionizing radiology by delivering a cloud-native platform that unifies the worklist, viewer, reporter, archive, and AI into a single, intuitive workspace. Designed specifically for radiologists, Sirona’s platform simplifies complex workflows, enhances productivity, and empowers practitioners to work as fast as they think.Founded in San Francisco, CA, Sirona combines deep expertise in the practice and business of radiology to create purpose-built solutions that address the evolving needs of the field. By streamlining radiology workflows and integrating cutting-edge AI, Sirona enables radiologists to deliver better, faster, and more efficient care.
Third Rock Ventures invests in transformational life science companies that show high growth potential and are well-positioned to make a difference in the marketplace. Third Rock Ventures believes in the companies we start and makes significant initial investments, which are frequently supplemented by strategic collaborations, to help our firms progress in life-changing medicines, technologies, and diagnostics.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Series B, Series C
- Geography: United States, Japan, Israel
Investor stats
- Total investments: 179
- Round size: Series A $19M–$110M; Series B $11M–$190M; Series C $20M–$108M
- Lead/follow: 46% lead, 54% follow
- Last fund: Likely still investing — raised $1.1B in 2022
Portfolio highlights
- CytomX Therapeutics — CytomX Therapeutics is a biotechnology company that focuses on developing proteolytically-activated antibodies. Their mission, alone and with the help of partners, is to provide patients with more effective and less toxic therapies for severe illnesses such as cancer and inflammatory diseases.
- Jounce Therapeutics — Concentra is a biosciences company.
- Lisata Therapeutics — Lisata is a clinical-stage pharmaceutical company dedicated to improving lives through the discovery, development, and commercialization of innovative medicines.
Northpond Ventures is a science-driven venture capital firm headquartered in Bethesda, Maryland. Our mission is to build a better tomorrow. Our investments are focused on life sciences, technology, and affiliated industries.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Life Science
- Stage:Series A, Series B, Series C
- Geography: United States, United Kingdom, Canada
Investor stats
- Total investments: 152
- Round size: Series A $13M–$65M; Series B $15M–$95M; Series C $23M–$85M
- Lead/follow: 59% lead, 41% follow
Portfolio highlights
- Culture Biosciences — Culture Biosciences provides a platform of cloud-connected bioreactors, software tools, and process development services that support upstream bioprocess development for biotech and biopharma applications. The company’s offerings include remote experiment design, monitoring, and data analysis through an integrated cloud software interface pairedwith single-use bioreactors for microbial fermentation and cell culture experimentation. Its services encompass clone and strain screening, process optimization, characterization, and bioprocess modeling to help scientific teams refine and scale their workflows. Clients access real-time data and analytics to inform decisions and collaborate across teams using the platform’s tools. Culture Biosciences’s technology is used to advance development of therapeutics, synthetic biology products, and related bioprocesses. Culture Biosciences was founded in 2016 and is headquartered in San Francisco, California.
- OMass Therapeutics — OMass Therapeutics is a drug discovery company exploiting novel mass spectrometry platforms to develop therapeutics against challenging disease targets.
- EnPlusOne Biosciences — EnPlusOne Biosciences provides innovative solutions for emerging RNA therapeutics.
RA Capital Management is an investment advisor based in Boston specializing in the life-sciences and drug development sectors. The company's team has been investing since 2002 and is comprised of professionals with training in biology, chemistry, and medicine and also has industry and business development experience at the executive and boardlevels. The company invests in companies with promising technologies and products.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series B, Post-IPO Equity, Series A
- Geography: United States, United Kingdom, China
Investor stats
- Total investments: 578
- Round size: Series A $20M–$128M; Series B $27M–$151M; Post-IPO Equity $35M–$275M
- Lead/follow: 35% lead, 65% follow
- Last fund: Likely actively investing — fresh fund, raised $120M in 2025
Portfolio highlights
- Serapha Bio —
- Windward Bio — Windward Bio is a clinical-stage, drug development company committed to improving outcomes for people living with serious immunological diseases.
- Lisata Therapeutics — Lisata is a clinical-stage pharmaceutical company dedicated to improving lives through the discovery, development, and commercialization of innovative medicines.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Leading Global Healthcare Platform with Deep Proprietary Resources and Global Industry Coverage.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Pharmaceutical
- Stage:Series B, Series A, Series C
- Geography: United States, China, Israel
Investor stats
- Total investments: 767
- Round size: Series A $9M–$116M; Series B $23M–$148M; Series C $19M–$160M
- Lead/follow: 35% lead, 65% follow
- Last fund: Likely actively investing — fresh fund, raised $192M in 2026
Portfolio highlights
- Windward Bio — Windward Bio is a clinical-stage, drug development company committed to improving outcomes for people living with serious immunological diseases.
- InventisBio — InventisBio is a biotech company whose product pipeline includes small molecule drug candidates for targeted therapies in lung cancer, breast cancer and gout. The company is also actively developing drugs that can be combined with other immune-oncology targeted therapies, such as PD-1 antibody, for various cancer indications. The company isco-founded by Dr. Yaolin Wang and other scientists who have previously worked at Merck and Schering-Plough, leading various drug discovery projects in oncology, metabolic and infectious disease areas.
- Bonovo Orthopedics —
Andreessen Horowitz (a16z) is a venture capital firm in Silicon Valley, California, investing in bold founders, innovators, and entrepreneurs building the future through technology.
Show more...Investment focus
- Industry: Software, Artificial Intelligence, Information Technology
- Stage:Series A, Seed, Series B
- Geography: United States, United Kingdom, Canada
Investor stats
- Total investments: 2143
- Round size: Seed $1.5M–$16M; Series A $9M–$55M; Series B $17M–$120M
- Lead/follow: 49% lead, 51% follow
- Last fund: Likely actively investing — fresh fund, raised $1.2B in 2026
Portfolio highlights
- Tennr — Tennr is a custom AI assistant that accelerates research, answers complex questions, and generates custom reports.
- Stoïk — Stoïk is a cyber insurance company that integrates cybersecurity software with insurance protection, helping businesses manage their cyber risks effectively. Stoïk empowers brokers by offering clients comprehensive insurance policies and protection against cyber risks. Its mission is to equip brokers with the tools to help their clients insure andsafeguard against cyber threats.Stoïk's unique product simplifies the underwriting process using automated tests, replacing traditional questionnaires. It also provides continuous risk prevention through integrated cybersecurity tools and ensures swift, effective incident response with an in-house team of crisis management experts.
- Phota Labs — Phota for iOS is coming soon. Phota Studio and the Phota API keep the same person consistent across AI images and video on any model.
Gaingels is a venture investment syndicate in service of the LGBT+ community and its allies, investing in companies with LGBT+ founders and C-suite leaders at all stages of growth, as well as in more established companies resolved on building more inclusive teams, with a global portfolio of 130+ companies and $70M in deployed investment capital to date. The Gaingels network also actively supports its portfolio in identifying and recruiting diverse talent to their C-suite and board leadership teams and fosters a vibrant global community of industry leaders, investors, operators, and entrepreneurs who share a common goal for positive social change through business and successful investments.
Show more...Investment focus
- Industry: Software, Artificial Intelligence, Health Care
- Stage:Seed, Series A, Venture - Series Unknown
- Geography: United States, Canada, United Kingdom
Investor stats
- Total investments: 1354
- Round size: Seed $1M–$8.1M; Series A $5M–$35M; Venture - Series Unknown $72k–$13M
- Lead/follow: 1% lead, 99% follow
- Last fund: Likely actively investing — fresh fund, raised $140k in 2026
Portfolio highlights
- Allara — Allara is your all-in-one virtual care team for hormonal, metabolic & gynecological conditions such as PCOS and Endometriosis.
- North.cloud — Automate your enterprise-grade cloud finance with zero effort. Our AI reduces your cloud bill by 50% without any risk, contracts, or technical work.
- Uvi — Uvi provides infrastructure that serves as a context and reasoning layer for enterprise AI agents. The platform resolves internal corporate vocabulary, tracks dependencies, and reconstructs the decision-making intent scattered across disparate systems like Jira, GitHub, and Slack. By unifying data fragments into an integrated knowledge network, it enables AI tools to process query objectives accurately while enforcing existing user access permissions at the retrieval stage.
GV supports innovative founders moving the world forward.
Show more...Investment focus
- Industry: Software, Health Care, Biotechnology
- Stage:Series A, Series B, Seed
- Geography: United States, United Kingdom, Israel
Investor stats
- Total investments: 1517
- Round size: Seed $1.1M–$15M; Series A $6M–$100M; Series B $15M–$121M
- Lead/follow: 30% lead, 70% follow
- Last fund: May invest from a new fund soon — raised $100M in 2014
Portfolio highlights
- SolveAI —
- Smarterer — Individuals and Fortune 500 companies use Smarterer to help close the gap between the skills they have and the skills they need. Their dynamic assessment engine leverages the freshest crowdsourced tests around, to rapidly pinpoint skill level with a credible score. In November 2014, Pluralsight, the global leader in online learning for serioussoftware developers, IT specialists and creative technologists, acquired Smarterer. As the world's largest curated e-learning library for professionals, the company offers instant access to more than 3,500 courses authored by top experts. Smarterer will continue to power crowdsourced assessments for freelancer marketplaces, e-learning providers and enterprise companies anywhere people need to prove their skills to connect with professional opportunities. The Smarterer community has answered over 56 million during 1.7 million test sessions, across hundreds of tests.
- EveryONE Medicines — EveryONE Medicines develops nucleic acid therapeutics for pathogenic genetic mutation of patients.
Liquid 2 Ventures is a venture capital firm that invests in early-stage startups, primarily at the pre-seed and seed stages. It provides capital, founder guidance, operational support, and access to a network of entrepreneurs, investors, and industry contacts.
Show more...Investment focus
- Industry: Software, Artificial Intelligence, Information Technology
- Stage:Seed, Pre-Seed, Series A
- Geography: United States, Mexico, Canada
Investor stats
- Total investments: 1249
- Round size: Seed $1.1M–$9.1M; Pre-Seed $125k–$2.7M; Series A $6M–$48M
- Lead/follow: 1% lead, 99% follow
- Last fund: Likely actively investing — fresh fund, raised $12M in 2026
Portfolio highlights
- Albedo — Aerial quality imagery - from space.
- Hilt — Govern data movement in real time. Kernel-level telemetry and anomaly detection built for environments where traditional security tools fall short.
- Eden — Eden unifies medical imaging operations with clinical AI: PACS, teleradiology, AI-assisted diagnosis and structured reporting, deployed across 2,600+ imaging departments.
We are deep tech venture capital.
Show more...Investment focus
- Industry: Software, Artificial Intelligence, Machine Learning
- Stage:Seed, Series A, Series B
- Geography: United States, United Kingdom, Canada
Investor stats
- Total investments: 518
- Round size: Seed $1M–$9.1M; Series A $6M–$50M; Series B $15M–$130M
- Lead/follow: 23% lead, 77% follow
- Last fund: Likely actively investing — fresh fund, raised $5M in 2026
Portfolio highlights
- CH4 Global — CH4 Global is an aquaculture solutions provider dedicated to urgently impacting climate change at scale. Lead by a world-class team of senior business builders, scientists and entrepreneurs, the company is initially leveraging proven science and technology for growing seaweed into innovative new livestock supplement that reduces methane produced bycows by up to 90%. Among early investors are a select group of prominent family offices and private investors. CH4 Global have also received non-dilutive capital support from government organizations from around the world. CH4 Global is a Delaware corporation based in Henderson, NV.
- TypeSafe AI — TypeSafe AI develops artificial intelligence models and software tools designed to support automated decision-making within applications and business workflows. Its primary product, Jev, is a System One Model that processes structured questions and returns typed decisions accompanied by probability scores and confidence estimates. These outputs help software systems perform tasks such as classification, scoring, routing, content evaluation, and customer service operations. TypeSafe AI provides an application programming interface and a web-based console that enable developers and organizations to integrate Jev into their existing systems. Its technology uses a training approach called Reinforcement Learning for Calibrated Decisions, which focuses on producing decisions that software can interpret and apply directly. The platform also supports configurable confidence thresholds, allowing applications to automate actions when confidence meets defined criteria or direct uncertain cases for human review. Through these capabilities, TypeSafe AI focuses on making AI-driven decisions usable in structured, programmatic workflows.
- Universal Quantum — Universal Quantum is building quantum computers to tackle real-world problems that would take today’s fastest supercomputers billions of years to solve.
Learn about the approach the Novartis Venture Fund takes to investing in innovative life science companies developing biotechnology and biopharmaceutical therapeutics that address unmet patient needs.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series B, Series A, Series C
- Geography: United States, Switzerland, United Kingdom
Investor stats
- Total investments: 237
- Round size: Series A $5.1M–$81M; Series B $11M–$107M; Series C $9M–$75M
- Lead/follow: 25% lead, 75% follow
- Last fund: May invest from a new fund soon — raised $200M in 2009
Portfolio highlights
- Kynexis — Kynexis is leading the way in precision medicine, focusing on the treatment of cognitive impairment associated with schizophrenia (CIAS). Explore our innovative approach and our dedication to improving the lives of millions globally.
- Visiogen — Visiogen, Inc. is an ophthalmic medical device company specializing in the development of new vision alternatives for patients with cataracts, with and without presbyopia. As part of this mission, Visiogen created the Synchrony dual optic accommodating *intraocular lens (IOL)* for use in the surgical treatment of these conditions.The device isdesigned to provide patients with near, intermediate and distance vision in a seamless continuum without the need for glasses or contact lenses. To eliminate lens handling during surgery, the Synchrony dual optic IOL is provided in a pre-loaded injector. This patented technology has been approved in Europe with a CE Mark designation and is currently undergoing clinical trials in the United States.
- Rein Therapeutics — Rein Therapeutics is advancing a novel pipeline of first-in-class medicines to address unmet medical needs in orphan pulmonary and fibrosis indications.
WE BACK HEROES using technology to solve the world's biggest problems
Show more...Investment focus
- Industry: Biotechnology, Health Care, Artificial Intelligence
- Stage:Seed, Series A, Pre-Seed
- Geography: United States, Germany, Canada
Investor stats
- Total investments: 216
- Round size: Seed $2M–$13M; Pre-Seed $572k–$3.3M; Series A $8.5M–$40M
- Lead/follow: 17% lead, 83% follow
- Last fund: Likely still investing — raised $90M in 2021
Portfolio highlights
- Wafer — Wafer is an AI optimization platform that automatically accelerates AI models by generating efficient custom GPU kernels.
- Adaption Labs — Adaption is building adaptive intelligence that continually learns. Efficient, evolving AI for any industry or language.
- Multiply Labs — Multiply Labs develops robotic systems that manufacture small-batch drugs. Current pharma production methods are manual, slow, and costly. We believe that the only way to scale them is with cloud-controlled robots.
Backing founders building iconic companies that transcend boundaries
Show more...Investment focus
- Industry: Software, Artificial Intelligence, SaaS
- Stage:Series A, Seed, Series B
- Geography: United States, Canada, United Kingdom
Investor stats
- Total investments: 712
- Round size: Seed $1.5M–$14M; Series A $4.4M–$42M; Series B $10M–$76M
- Lead/follow: 27% lead, 73% follow
- Last fund: Likely actively investing — fresh fund, raised $900M in 2025
Portfolio highlights
- Arena — Moved to @arena
- Sooth Labs —
- Solcoa Industries — Solcoa Industries develops carbon-zero rare earth metals for critical supply chain needs and promote sustainable industrial practices
Supporting early stage Life Science startups driving patient impact. Born from our collective experience as founders, we set out to build the fund we wanted to raise from....
Show more...Investment focus
- Industry: Health Care, Biotechnology, Life Science
- Stage:Seed, Series A, Pre-Seed
- Geography: United States
Investor stats
- Total investments: 24
- Round size: Seed $2M–$12M; Pre-Seed $2.7M–$2.7M; Series A $12M–$70M
- Lead/follow: 13% lead, 87% follow
Portfolio highlights
- iOrganBio — iOrganBio is a pioneering cell production platform that uses CellForge to facilitate the intelligent manufacturing of human cells and organoids.
- Galatea Bio — Galatea Bio, a US-based biotechnology company was founder by Carlos Bustamante, Nicholas Katsanis and Alexander Ioannidis. Our mission is to drive groundbreaking discoveries in healthcare by pairing genetic diversity with cutting-edge data analytics. Our passion is fueled by a focus on populations historically underrepresented in genetics research.We achieve this by leveraging our world-class clinical network and biobank, cutting-edge algorithms, and innovative analyses to discover and validate new tests, treatments, and cures that will improve the lives of all.
- Italic Health — Italic Health, Inc. is a healthcare technology company building a unified platform for managing patient data, medical billing, and insurance workflows. Its software integrates health records, appointment scheduling, and AI-driven analytics to improve care coordination, financial processes, and patient engagement.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!KdT Ventures is the standard for early-stage frontier science investing.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Seed, Series A, Series B
- Geography: United States, India, Canada
Investor stats
- Total investments: 96
- Round size: Seed $2.6M–$13M; Series A $9M–$70M; Series B $25M–$175M
- Lead/follow: 9% lead, 91% follow
- Last fund: Likely actively investing — fresh fund, raised $4.9M in 2026
Portfolio highlights
- Zag Bio — Zag Bio is harnessing the immune system in a whole new way by targeting the thymus to change treatment possibilities for millions of patients with autoimmune diseases.
- Skeletalis — Skeletalis is a biotechnology startup focused on developing next-generation precision medicines for musculoskeletal diseases, primarily osteoporosis.
- Tacit Therapeutics — Tacit Therapeutics created RNA-targeting treatments for devastating diseases. By repurposing pre-existing components of human cells, we have created the first broadly applicable and inherently non-immunogenic means to repair mutated genes. The company was founded in 2021 and is based in South San Francisco, California.
We create breakthroughs in human health and sustainability and build bioplatform companies . Companies founded
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series B, Series C, Series A
- Geography: United States, Canada, United Kingdom
Investor stats
- Total investments: 257
- Round size: Series A $6.6M–$75M; Series B $11M–$230M; Series C $12M–$123M
- Lead/follow: 47% lead, 53% follow
- Last fund: Likely still investing — raised $2.6B in 2024
Portfolio highlights
- ZoomInfo — ZoomInfo is the #1 GTM Platform: Marketing and sales AI plus the best B2B data. All-in-one lead generation, prospecting, market intelligence , and ABM software.
- iris labs — Iris Labs is an AI company focused on improving human wellbeing through personalized AI experiences for self-awareness, and personal growth.
- Serif Biomedicines — Serif Biomedicines is pioneering Modified DNA as a new type of biotechnology. Serif combines nucleic acid chemistry, synthetic biology, delivery technology, and artificial intelligence to develop programmable, scalable, long-lasting, and redosable DNA therapies.
We are a multi-stage investment firm, investing in companies that leverage biology and big data to transform healthcare.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series B, Series C, Series A
- Geography: United States, United Kingdom, China
Investor stats
- Total investments: 225
- Round size: Series A $17M–$165M; Series B $24M–$140M; Series C $37M–$270M
- Lead/follow: 28% lead, 72% follow
- Last fund: Likely still investing — raised $900M in 2024
Portfolio highlights
- Thyme Care — Thyme Care is a dedicated team of nurses and care experts offering value-based cancer care to help you through all phases of the cancer experience.
- Korsana Biosciences — Korsana Biosciences develops THETA-enabled antibody therapies for neurodegenerative diseases. The company focuses on shuttled monoclonal antibodies that cross the blood-brain barrier to reach central nervous system targets. Its lead program, KRSA-028, is an investigational anti-amyloid beta antibody for Alzheimer’s disease that uses a transferrinreceptor-based shuttle and Fc engineering to improve brain delivery and dosing. Korsana is also advancing additional THETA-based programs for undisclosed neurodegenerative indications.
- Khartis Therapeutics — Khartis is a drug discovery company developing oral therapies for patients with immune-mediated and chronic diseases. The company focuses on discovering and developing drug candidates intended to address chronic conditions and immune-mediated diseases.
ATP, a global leader in life sciences venture capital, is developing the next generation of transformative biotechnology companies. ATP creates science-based companies starting with assets at various stages: from working with scientists on pre-IP ideas, to spinouts from existing company pipelines. The firm provides flexible capital, strategic insight, and operational resources to build sustainable, research-driven enterprises. ATP invests in its portfolio companies from seed stage through IPO and beyond and supports their management teams in strategic transactions and synergistic business combinations.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Series B, Seed
- Geography: United States, Canada, United Kingdom
Investor stats
- Total investments: 100
- Round size: Seed $3.5M–$8M; Series A $15M–$75M; Series B $29M–$100M
- Lead/follow: 63% lead, 37% follow
- Last fund: May invest from a new fund soon — raised $1B in 2020
Portfolio highlights
- Ascidian Therapeutics — Ascidian Therapeutics is a biotechnology company intended for medical use in medical and clinical gene therapy.
- Red Queen Therapeutics — Staying ahead of viral threats with new innovations in antiviral therapy
- Deep Apple Therapeutics — Deep Apple Therapeutics is discovering new small-molecule therapeutics with unprecedented speed and exceptional acumen.
Lux Capital focuses on sectors such as artificial intelligence, biotechnology, advanced materials, space, and energy, backing businesses that apply scientific research to commercial applications. It provides capital alongside strategic input on product development, company building, and long-term positioning. The firm works with technical founders and research-driven teams to translate complex innovations into scalable businesses. It evaluates opportunities based on the underlying science, potential for industry impact, and feasibility of execution over extended time horizons.
Show more...Investment focus
- Industry: Software, Artificial Intelligence, Health Care
- Stage:Series A, Seed, Series B
- Geography: United States, United Kingdom, Canada
Investor stats
- Total investments: 706
- Round size: Seed $1.6M–$25M; Series A $7M–$90M; Series B $13M–$150M
- Lead/follow: 28% lead, 72% follow
- Last fund: Likely actively investing — fresh fund, raised $10M in 2026
Portfolio highlights
- Adimab — Premier Human Antibody Discovery and Optimization
- Modal Labs — Modal develops machine learning software to help run code in the cloud. The software enables users to run or deploy machine learning models, massively parallel compute jobs, task queues, web apps, and more. It also writes the code to launch hundreds of custom containers and runs scripts in the cloud faster than on the local machine.
- Cajal Neuroscience — Cajal Neuroscience is a drug discovery company focused on neurodegenerative disease.
TCA Venture Group is the largest angel investor group in the United States, possessing more than 300 members in five networks in Los Angeles, Orange County, San Diego, Central Coast, and the Inland Empire. Its members provide funding and guidance to more early-stage, high-growth companies in Southern California than any other investment group. Members invest in companies in a wide range of industries, including the life sciences, biotech, IT, services, retail, Internet, financial, software, media, consumer products, and tech startups. TCA as a whole gives companies more than just capital; they also provide counsel, mentoring, and access to an extensive network of potential investors, customers, strategic partners, and management talent. Tech Coast Angels has been ranked by CB Insights to be among the Top 20 Angel Groups in the US; TCA was also ranked as #1 for Network Centrality, meaning we have more connections than anyone! If you are in the game-changing business, we are here to help.
Show more...Investment focus
- Industry: Health Care, Software, Biotechnology
- Stage:Seed, Venture - Series Unknown, Convertible Note
- Geography: United States, Canada, South Africa
Investor stats
- Total investments: 396
- Round size: Seed $525k–$3.8M; Convertible Note $50k–$4.5M; Venture - Series Unknown $400k–$8.5M
- Lead/follow: 9% lead, 91% follow
- Last fund: May invest from a new fund soon — last raise in 2015
Portfolio highlights
- EdgeX — Edokonta builds software that allows hospitals to track mobile equipment, such as IV pumps and ultrasounds. The company was founded in 2018 and based in San Diego, California.
- Nested Knowledge — Nested Knowledge is designing an interface that allows you to examine the data from a comprehensive literature review on research questions of interest. The interactive, nested features facilitate therapeutic comparisons, assist with research organization, and allow physicians to compare nuances across patient characteristics and outcomes.
- Major Medical Devices — Major Medical Devices develops next-generation vascular devices for endovascular repair and related surgical procedures.
Cormorant Asset Management is an employee-owned hedge fund sponsor that provides its services to pooled investment vehicles. The firm also focuses on both public and private market innovative companies in the biotechnology and life sciences marketplace.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series B, Series C, Series A
- Geography: United States, China, Switzerland
Investor stats
- Total investments: 254
- Round size: Series A $16M–$102M; Series B $27M–$150M; Series C $30M–$146M
- Lead/follow: 24% lead, 76% follow
- Last fund: Likely actively investing — fresh fund, raised $75M in 2025
Portfolio highlights
- Epicrispr Biotechnologies — The Gene Expression Modulation System (GEMS) technology from Epic-Bio combines a DNA-binding protein, a tailored guide RNA, and any of a wide range of modulator proteins to generate a powerful new type of genetic medicine. GEMS medicines have the ability to precisely modify gene expression both in and out of the body. They are mutation-independent,which means that a single GEMS design can address the majority or all genetic subtypes of a disease.
- Processa Pharmaceuticals — Processa Pharmaceuticals is committed to developing drug products aimed at improving the quality of life for patients with unmet medical needs.
- Cue Biopharma — A precision immuno-engineering company targeting transformative therapies for patients with significant unmet needs across allergic and autoimmune diseases.
The Column Group (TCG) is a venture ecosystem dedicated to fueling scientific innovation in the life sciences industry.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Series B, Series C
- Geography: United States
Investor stats
- Total investments: 165
- Round size: Series A $15M–$102M; Series B $22M–$120M; Series C $37M–$120M
- Lead/follow: 38% lead, 62% follow
- Last fund: Likely still investing — raised $100M in 2024
Portfolio highlights
- Kallyope — At TriGemX Bio, we are leveraging unique insights into neural signaling pathways and developing innovative medicines for the treatment of migraine.
- InduPro — InduPro is a biotechnology company that specializes in protein therapeutics and cell-surface platform technologies.
- Circle Pharma — Circle Pharma is an early-stage biotechnology company applying proprietary computational design algorithms and innovative chemistry to develop cell-permeable macrocycle peptide therapeutics against important clinical targets. It does this through an iterative, rational design process that deploys large virtual libraries of conformationally diversemacrocycle scaffolds selected for inherent permeability. The company was founded by Matt Jacobson and Scott Lokey in 2012 and is headed by David J. Earp.
Investing in powerful, positive change that endures
Show more...Investment focus
- Industry: Software, Artificial Intelligence, Health Care
- Stage:Seed, Series A, Series B
- Geography: United States, India, United Kingdom
Investor stats
- Total investments: 2301
- Round size: Seed $1.6M–$18M; Series A $6.7M–$75M; Series B $14M–$123M
- Lead/follow: 46% lead, 54% follow
- Last fund: Likely actively investing — fund raised in 2026
Portfolio highlights
- Lemonade — Lemonade operates as a full-stack insurance company powered by AI and behavioral economics and driven by social good. It is a licensed insurance carrier, offering homeowners and renters insurance. Lemonade replaces brokers and bureaucracy with bots and machine learning, delivering zero paperwork and instant everything. The company uses artificialintelligence and behavioral economics to set rates for the homes and renters it insures. Lemonade was founded in Tel Aviv, Israel, in 2015 and is headquartered in New York, NY, United States.
- Datalogix — Datalogix® is the industry-recognized leader at connecting digital media and offline purchasing data. We help more than half of the top 100 consumer marketers increase the effectiveness and measurability of their advertising. DLX Platform®, encompasses over $1 trillion in consumer spending and powers campaigns for more than 75% of online mediacompanies. DLX ROI® is rapidly becoming the industry standard for measuring offline sales lift for digital media. Datalogix also offers predictive analytics for Direct Mail, and integrated media solutions via the DLX Net. Our expertise spans the major consumer segments, including Retail, CPG, Automotive, Telecom, Travel and Financial Services. We are based in Colorado, with offices in New York City, San Francisco, Boston, Chicago, Detroit, and London.
- Relay — Relay (Relay Financial), is an all-in-one business banking and money management platform helping businesses understand what they're earning, spending & saving.
Pear VC partners with entrepreneurs from day zero to build category-defining companies.
Show more...Investment focus
- Industry: Software, Artificial Intelligence, Information Technology
- Stage:Seed, Pre-Seed, Series A
- Geography: United States, Brazil, Colombia
Investor stats
- Total investments: 528
- Round size: Seed $1.6M–$9M; Pre-Seed $175k–$3.5M; Series A $8.5M–$40M
- Lead/follow: 19% lead, 81% follow
- Last fund: Likely still investing — raised $3.4M in 2024
Portfolio highlights
- Presonance — Presonance provides brain-based creative testing for agencies and research partners. Its platform simulates audience responses to videos, images, and scripts to assess how creative content may influence viewer behavior. Users can analyze audience responses moment by moment and use the results to evaluate and refine campaigns before launch. Presonance also provides sample analyses and research-backed insights for creative testing.
- Phinity Labs — Phinity Labs builds AI systems designed to fully automate the entire silicon microchip engineering process, spanning from original architectural concepts to final manufacturing preparation.
- Hertha Metals — At Hertha Metals, we are developing advanced steel solutions to accelerate the growth and global competitiveness of the U.S. steel industry.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Khosla Ventures is a venture capital firm that invests in early- to late-stage companies across sectors like AI, healthcare, sustainability, and consumer technology. It manages multiple funds, focusing on startups with innovative technologies or business models. The firm primarily targets sectors like AI, climate tech, digital health, and medtech, offering strategic support to help build long-lasting companies.
Show more...Investment focus
- Industry: Artificial Intelligence, Software, Health Care
- Stage:Series A, Seed, Series B
- Geography: United States, United Kingdom, India
Investor stats
- Total investments: 1508
- Round size: Seed $1.8M–$23M; Series A $5.5M–$47M; Series B $11M–$100M
- Lead/follow: 39% lead, 61% follow
- Last fund: Likely actively investing — fresh fund, raised $31M in 2026
Portfolio highlights
- Anrok — Anrok automates sales tax compliance across your financial stack, so you can grow your SaaS business in any market.
- Vectra AI — Vectra AI delivers AI-native security and observability across network, identity, cloud, SaaS, and AI environments to reduce exposure, accelerate response, and strengthen cyber resilience.
- C the Signs — Discover C the Signs: a cutting-edge cancer prediction system enhancing early detection and survival. Committed to reducing healthcare disparities.
Systematic Pre-Seed Startup Capital
Show more...Investment focus
- Industry: Software, Artificial Intelligence, SaaS
- Stage:Pre-Seed, Convertible Note, Seed
- Geography: United States, Canada, United Kingdom
Investor stats
- Total investments: 2082
- Round size: Seed $50k–$1.7M; Pre-Seed $50k–$450k; Convertible Note $50k–$400k
- Lead/follow: 3% lead, 97% follow
- Last fund: Likely actively investing — fresh fund, raised $55M in 2025
Portfolio highlights
- tbh — tbh is a developer of a mobile application designed to provide anonymous feedback to friends. The company's mobile application facilitates asking or answering questions, open text fields and invite abuse when combined with anonymity, enabling users to say things without repercussions and feel better about themselves from the positive feedbackon social networks.
- Athel AI — Athel AI provides an AI-powered clinical intake platform for physicians and healthcare teams. Its tools conduct patient interviews through voice, chat, and video, capture clinical histories, and generate structured summaries for physicians. The platform also supports AI-assisted reception, dictation, multilingual interviews, and automated clinical workflows. Athel AI provides clinical decision support while keeping diagnosis and treatment decisions under the physician's authority.
- Vidrovr — Vidrovr develops multimodal computer vision and machine learning systems to index, tag, and understand video. It processes videos with specific domain constraints, such as in sports, government, and media verticals. Its technology enables its users to search an indexed video corpus and retrieve content inside videos and link it to other media likephotos and text.The company Integrates social media to enable direct interactions between multimedia content. Vidrovr was founded in 2016 and is headquartered in New York.
We are an early-stage venture capital firm investing in transformative companies harnessing information growth and computing power to change the world.
Show more...Investment focus
- Industry: Software, Artificial Intelligence, Machine Learning
- Stage:Series A, Seed, Series B
- Geography: United States, Canada, Mexico
Investor stats
- Total investments: 275
- Round size: Seed $1.5M–$8M; Series A $7.5M–$70M; Series B $15M–$120M
- Lead/follow: 25% lead, 75% follow
- Last fund: Likely still investing — raised $400M in 2022
Portfolio highlights
- Swarm Aero — Swarm empowers small teams to mobilize thousands of uncrewed vehicles in communications-limited, contested environments.
- Artemis — Artemis is the first protective layer that is AI-native
- littleBits Electronics — LittleBits is an open source library of over 60 electronic modules that snap together with magnets allows users to view, download, and share designs and make their own Bits through the use of prototypes. Deluxe kit, Smart home kit, Arduino coding kit, Synth kit, hardware development kit, and workshop set are some of the electronics learning modulesprovided by littleBits.LittleBits was launched by Ayah Bdeir in 2011 and is operated from New York, United States.
Powering Breakthroughs in Life Sciences
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series B, Series A, Series C
- Geography: United States, Canada, United Kingdom
Investor stats
- Total investments: 241
- Round size: Series A $10M–$80M; Series B $20M–$116M; Series C $12M–$109M
- Lead/follow: 35% lead, 65% follow
- Last fund: Likely still investing — raised $850M in 2021
Portfolio highlights
- Orna Therapeutics — Orna Therapeutics is a biotechnology company dedicated to designing and delivering a new class of fully engineered circular RNA (oRNA) therapeutics with the potential to change the way we treat disease. Orna’s proprietary platform combines novel technology to create oRNAs that drive protein expression with validated and unique delivery solutions.
- Aratana Therapeutics — Aratana is uniquely positioned to deliver new, high-quality medicines to address unmet needs in companion animal care. We are committed to bringing world class science to animal health for companion animals and the people who care for them. Our competitive advantage resides in our ability to identify, acquire and develop high-value commercialproducts for companion animals in a cost effective and efficient manner.
- Rhythm Pharmaceuticals — Rhythm Pharmaceuticals is a global biopharmaceutical company committed to transforming the lives of patients with rare neuroendocrine diseases by rapidly advancing care and precision medicines that address the root cause.
We aim to invest in exceptional founders and entrepreneurs and impactful products and platforms across multiple therapeutic areas.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Series B, Series C
- Geography: United States, Switzerland, United Kingdom
Investor stats
- Total investments: 172
- Round size: Series A $16M–$200M; Series B $38M–$165M; Series C $14M–$208M
- Lead/follow: 28% lead, 72% follow
- Last fund: Likely still investing — raised $470M in 2023
Portfolio highlights
- Ousia Pharma — Ousia Pharma is paving the way for novel therapeutic strategies using peptide-drug-conjugates
- Windward Bio — Windward Bio is a clinical-stage, drug development company committed to improving outcomes for people living with serious immunological diseases.
- Anaconda BioMed — Anaconda Biomed, headquartered in Barcelona, Spain, is among the world's most innovative early stage medical technology companies. The company was founded by Dr. Ofir Arad and Dr. Marc Ribó in 2015, and is developing the ANCD BRAIN™, a novel 3rd Generation Stented Aspiration Thrombectomy System for the treatment of Acute Ischemic Stroke (AIS).
Early stage venture capital backed by some of the world's best entrepreneurs.
Show more...Investment focus
- Industry: Software, Artificial Intelligence, Financial Services
- Stage:Seed, Pre-Seed, Series A
- Geography: United States, United Kingdom, India
Investor stats
- Total investments: 514
- Round size: Seed $1.5M–$10M; Pre-Seed $250k–$3.5M; Series A $7M–$22M
- Lead/follow: 20% lead, 80% follow
- Last fund: May invest from a new fund soon — raised $125M in 2021
Portfolio highlights
- microagi — microagi is a data research lab working on end-to-end physical AGI, with a focus on reliable real-world deployments.
- Legato Audio — Legato Hearing develops stylish glasses with built-in hearing technology, offering a discreet alternative to traditional hearing aids.
- Cast Insights — Cast Insights is an AI-powered platform that turns global spoken content—TV, radio, podcasts, livestreams—into structured, searchable real-time intelligence for investors, policy teams, strategists, and newsrooms.
DIGITAL HEALTH / AI DIGITAL HEALTH / AI GENE / CELL THERAPIES NASDAQ: RCKT GENE / CELL THERAPIES NASDAQ: RCKT GENOMICS / DIAGNOSTICS GENOMICS / DIAGNOSTICS SYNTHETIC
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Seed, Series A, Series B
- Geography: United States, United Kingdom, Brazil
Investor stats
- Total investments: 77
- Round size: Seed $1.8M–$16M; Series A $8.1M–$30M; Series B $24M–$144M
- Lead/follow: 3% lead, 97% follow
- Last fund: May invest from a new fund soon — raised $35M in 2020
Portfolio highlights
- OxCan — Enabling curative cancer treatment through early detection
- Rinascera Therapeutics — Rinascera Therapeutics develops transformative therapies for rare genetic skin diseases, including RIN-001 for Gorlin Syndrome and RIN-002 for Dystrophic Epidermolysis Bullosa (DEB).
- Sensible Biotechnologies — Engineering cells to make better mRNA.
F-Prime Capital is a global venture capital firm investing in healthcare and technology, with a heritage that spans four decades.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical
- Stage:Series A, Series B, Seed
- Geography: United States, China, United Kingdom
Investor stats
- Total investments: 548
- Round size: Seed $1.6M–$20M; Series A $8M–$87M; Series B $15M–$112M
- Lead/follow: 25% lead, 75% follow
Portfolio highlights
- Innovent Biologics — Innovent Biologics, Inc. is a privately held biopharmaceutical company that is dedicated to the development and manufacturing of monoclonal antibodies to be marketed in China and elsewhere around the world. Innovent is funded by the venture arm of Fidelity, which is a major investment firm in the US, Lilly Ventures, and Suzhou bioBay. Theregistered capital is 30Million US Dollars. The founders and senior management team of Innovent have over 70 years of combined work experience in the discovery, development and manufacture of biologics in the US, Europe and worldwide and were involved in the launch of such products as Bexxar, Conbercept, Natrecor, Oncorine, Recombivax HB, and others.
- Mersana Therapeutics — Discover how Day One is disrupting the status quo of traditional drug development to bring new medicines to children and adults with cancer.
- PlasmaGen Biosciences — PlasmaGen BioSciences is an Indian Bio-pharmaceutical organization specializing exclusively in Plasma Protein Therapy.Headquartered in Bangalore- India, PlasmaGen has been making every effort in the domain of Plasma product Industry and has become an Imperative one stop destination for the medical fraternity for most of the plasma products need.They have a basket of plasma products and the widest range of immunoglobulins in India catering to the requisites of various realms viz. Haematology, Oncology, Immunology, Paediatrics, Rheumatology, Dermatology and Neurology.
Foundational partners to ambitious founders at every stage of company-building.
Show more...Investment focus
- Industry: Software, Health Care, Biotechnology
- Stage:Series A, Series B, Series C
- Geography: United States, China, India
Investor stats
- Total investments: 2100
- Round size: Series A $6M–$55M; Series B $10M–$85M; Series C $15M–$100M
- Lead/follow: 39% lead, 61% follow
- Last fund: Likely still investing — raised $468M in 2024
Portfolio highlights
- Uhana — Modernize your RAN to be open and programmable, built with a rich ecosystem of partners. Learn about VMware RAN Intelligent Controller (RIC).
- Zyngenia —
- Packeteer — Packeteer is a global leader in WAN Application Delivery and WAN Optimization. The company offers an integrated family of appliances and software products. Packeteer is a provider of network software products that enhance mission-critical application performance over enterprise WANs and the Internet. These application-adaptive bandwidth managementsolutions give businesses and service providers per-application control of bandwidth at congested WAN access links.
At Connecticut Innovations, we see venture capital the way you see your business. Like no one else. We invest in innovative biotech, IT, and other industries.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Software
- Stage:Seed, Series A, Series B
- Geography: United States, Israel, Canada
Investor stats
- Total investments: 315
- Round size: Seed $150k–$5.3M; Series A $1.8M–$25M; Series B $1.8M–$75M
- Lead/follow: 30% lead, 70% follow
- Last fund: Likely still investing — raised $50M in 2023
Portfolio highlights
- CloudSEK — CloudSEK leverages contextual AI to predict and prevent cyber threats. Keep your organisation safe and secure.
- NovaTract Surgical — NovaTract Surgical is a development stage company, intends to develop medical devices to address the rapidly growing field of Single Incision Laparoscopic Surgery (SILS) and Natural Orifice Transluminal Endoscopic Surgery (NOTES). The company was incorporated in 2010 and is based in Guilford, Connecticut.
- Axerion Therapeutics — Axerion Therapeutics, Inc. is a private Connecticut-based biotechnology company focused on developing innovative therapeutics for neurological diseases and injuries with significant unmet medical need, including Alzheimer’s disease and spinal cord injury.Axerion was established in New Haven to develop and commercialize intellectual propertylicensed from Dr. Stephen Strittmatter’s laboratory at Yale University. Axerion’s proprietary technology platforms include blockers of ß-amyloid (Aß) oligomers binding to Prion Proteins (PrP) on the cell surface of neurons as a novel therapeutic target for Alzheimer’s disease and Nogo Receptor decoy protein for recovery of neurological function in spinal cord injury and other neurological diseases.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Artis Ventures has spent over a decade backing bold teams who take the hard path, building market-defining companies to re-shape, re-invent, and re-make industries.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Software
- Stage:Series A, Series B, Seed
- Geography: United States, United Kingdom, India
Investor stats
- Total investments: 151
- Round size: Seed $2.1M–$35M; Series A $5M–$57M; Series B $20M–$127M
- Lead/follow: 39% lead, 61% follow
- Last fund: Likely still investing — raised $141M in 2023
Portfolio highlights
- GenHealth.ai — GenHealth.ai provides healthcare solutions using generative AI trained on encoded medical events. Its product is a generative healthcare AI publicly available. It includes a foundation transformer model (new neural networks with excellent memory), an API, and user applications that can generate and predict future sequences of health events usinghistorical events. Together they can be used to build a large variety of customized applications.
- Ozlo Sleep — Ozlo Sleep is a science-driven sleep and audio technology company that supports and simplifies sleep rituals for clinical benefits, without the use of medication.
- Stateless Networks — Performance, Visibility. Simplicity...It's time for a beautiful network. Stateless is transforming network operations for software-centric networking. Tying together deep network understanding with state-of-the-art distributed systems, cloud, data science and gaming expertise, Stateless transforms network visibility, performance andresponse and helps accelerate the transition to modern network platforms, tying together physical and virtual layers. Focused on the enterprise data center, Stateless currently partners with the world’s leading network and infrastructure vendors (including VMware (VMW), Cisco Systems (CSCO), Cumulus Networks and others) to deliver solutions to some of the world’s largest private data center operators. We’re looking for software and networking engineers in Greater Seattle and the Bay Area with expertise in one or more of the following areas: Distributed Systems, Service Oriented Architecture, Complex Event processing, Functional Programming, Virtualization, Network design and deployment, Network programming, Network troubleshooting, configuration and performance tuning and SDN. Bonus points for experience working with cloud infrastructure (AWS, Azure, OpenStack) or low-level systems software (linux kernel, hypervisors, compilers/language runtimes), complex gaming systems or graphics and computational geometry. For more information visit http://www.statelessnetworks.com/ or follow Stateless on Twitter: @statelessntwrks.see
Catalio Capital Management was created by George Petrocheilos and Dr. Jacob Vogelstein to invest in breakthrough biomedical technology companies created or referred by Catalio Capital Management, an elite group of world-renowned, serial scientist-entrepreneurs.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Series B, Series C
- Geography: United States, Israel, Switzerland
Investor stats
- Total investments: 151
- Round size: Series A $9.7M–$150M; Series B $26M–$130M; Series C $70M–$208M
- Lead/follow: 32% lead, 68% follow
- Last fund: Likely actively investing — fresh fund, raised $16M in 2026
Portfolio highlights
- OSPRI — OSPRI is updating the infectious illness testing plan. Established by the combination of Community Direct DX, Scienetix, and the R&D section of Advanta Genetics, OSPRI is among the first molecular testing platforms in the world to be entirely vertically integrated.
- BigHat Biosciences — We use machine learning and synthetic biology to design and engineer antibody therapeutics.
- Enveda Biosciences — Enveda exists to give hope to millions of people around the world by accelerating the discovery of better medicines.
SV Angel offers founders assistance with key inflection points, including capital raising, strategic networking, business development, talent acquisition, and corporate transactions. Through its relationship network, the organization connects emerging businesses with industry partners, executive advisors, and ecosystem resources. Additionally, the firm provides guidance on corporate governance, operational scaling, and management decisions to support technology enterprises throughout their growth stages.
Show more...Investment focus
- Industry: Software, Artificial Intelligence, Information Technology
- Stage:Seed, Series A, Series B
- Geography: United States, Canada, United Kingdom
Investor stats
- Total investments: 1402
- Round size: Seed $1M–$11M; Series A $3M–$35M; Series B $8.3M–$100M
- Lead/follow: 2% lead, 98% follow
- Last fund: Likely actively investing — fresh fund, raised $430M in 2025
Portfolio highlights
- Tab — Tab is an text-based AI assistant that acts as an execution agent rather than just an information provider. Developed by Terrasoft, Inc., it allows users to delegate actual workloads directly via their messaging app using text, photos, documents, or video.
- Hyperpublic — Hyperpublic is an open database of people, places, and things tied to a specific location. Anyone can add objects to the database and developers will be able to build applications on top of the data.
- SafeWorld — SafeWorld is a safety testing platform for companies deploying robots around people, helping them assess and improve the safety.
Playground Global is an early-stage venture capital firm backing technical and scientific founders with deep engineering expertise, a collaborative environment, and a first-hand understanding of the intricacies of deep tech. Established in 2015 and headquartered in Palo Alto, CA, Playground’s mission is to transform ambitious ideas into impactful businesses that benefit humanity and the planet. We invest in areas that span across next gen compute automation, energy transition and engineered biology. Playground has been an early – and frequently first investor – in companies that include PsiQuantum, Relativity Space, Ultima Genomics, MosaicML (acq. by Databricks), d-Matrix, and Strand Therapeutics.
Show more...Investment focus
- Industry: Software, Artificial Intelligence, Robotics
- Stage:Series A, Seed, Series B
- Geography: United States, Canada, Australia
Investor stats
- Total investments: 155
- Round size: Seed $2.3M–$14M; Series A $8M–$44M; Series B $20M–$150M
- Lead/follow: 50% lead, 50% follow
- Last fund: Likely actively investing — fresh fund, raised $475M in 2026
Portfolio highlights
- RegCell — RegCell aims to generate novel therapeutic technologies through augmenting or controlling the immune system and our goal is to save patients who suffer from autoimmune diseases and cancer .
- Mesa Quantum — Mesa Quantum's sensors are changing how systems perceive our world. Our mass-manufacturable, chip-scale sensors help machines know where they are, what time it is, and what's around them.
- Delos Data — Delos Data develops infrastructure technology for large-scale artificial intelligence workloads. The company focuses on addressing networking and memory bottlenecks in massive AI data centers by moving away from legacy high-performance computing and traditional cloud architectures. Its teams design custom software, systems, and silicon interconnects tailored for AI workloads, improving how compute tasks are distributed and how memory layers are interconnected. Delos Data offers the Nonstop AI platform, an architecture that optimizes memory connections across large GPU clusters to support fast, resilient inference domains. It also provides the Delos Mosaic software stack, which delivers real-time cluster analytics to detect bottlenecks and automatically reroute workflows during GPU or cable failures. These offerings target organizations building or operating advanced AI infrastructure that require improved performance, reliability, and scalability.
Venture investing in Food, Health, and AgTech. A generational investment thesis. Food is Health is longevity
Show more...Investment focus
- Industry: Biotechnology, Health Care, Agriculture
- Stage:Seed, Series A, Venture - Series Unknown
- Geography: United States, Canada, Australia
Investor stats
- Total investments: 118
- Round size: Seed $500k–$9M; Series A $600k–$41M; Venture - Series Unknown $1.2M–$24M
- Lead/follow: 14% lead, 86% follow
- Last fund: May invest from a new fund soon — raised $3.8M in 2019
Portfolio highlights
- Miraterra — A New Era of Measurement: Unlocking the Secrets of Soil, Plants, and Food. Our breakthrough technology, overcoming decades of limitations, provides fast, efficient and trustworthy digital measurements when and where you need them most.
- Mercy BioAnalytics — We are making early-stage cancer easier to find using extracellular vesicles found in blood, specific to their parent cells.
- Vive Crop Protection — Vive Crop Protection makes effective and sustainable pesticides for organic and non-organic production. The company creates new ways to use proven crop protection products using their targeted Allosperse Delivery System, which improves the targeting and performance of pesticide active ingredients. This helps farmers do more with less, all whileincreasing crop quality and yields.Vive Crop Protection was founded in 2006 and is headquartered in Mississauga, Ontario, Canada.
Hatteras Venture Partners is a venture capital firm based in Research Triangle Park, NC, with a focus on biopharmaceuticals, medical devices, diagnostics, and related opportunities in human medicine. Founded in 2000, the firm consists of an experienced team with a broad and complementary skill set that is particularly relevant to buildingsuccessful new biomedical companies. The Hatteras Venture Partners team brings operational experience, a successful track record, and a proven ability to enhance the value of the companies in which it invests. With three funds, the firm has more than $120 million under management.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical
- Stage:Series A, Series B, Series C
- Geography: United States, Canada
Investor stats
- Total investments: 142
- Round size: Series A $2.6M–$50M; Series B $5M–$82M; Series C $8M–$88M
- Lead/follow: 37% lead, 63% follow
- Last fund: Likely still investing — raised $30M in 2023
Portfolio highlights
- RapidPulse — Explore RapidPulse for innovative stroke treatments and technologies. Book appointments or learn about our team and clinical trials.
- 410 Medical — 410 Medical has developed a simple, intuitive solution that allows a single healthcare provider to rapidly deliver fluid to critically ill patients, improving care, and saving lives. Their device allows fast set-up, improves resuscitation speed, minimizes provider fatigue, and frees providers to address other patient care issues simultaneously.This solution is particularly useful in pre-hospital settings and the emergency department and where speed is critical and resources may be limited.It was founded in 2013 and headquartered in Durham, North Carolina.
- Ladder Health — Expert speech, occupational, physical, and feeding therapy for children, right from home, with flexible virtual visits and a plan that fits real life.
Sahsen Ventures is a venture capital firm making investments in for-profit and nonprofit organizations with an emphasis on technology and biotechnology. It was established in 2016 and is based in Seattle, Washington.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Non Profit
- Stage:Venture - Series Unknown, Seed
- Geography: United States, United Kingdom, China
Investor stats
- Total investments: 101
- Round size: Seed $1.2M–$25M; Venture - Series Unknown $1.5M–$135M
- Lead/follow: 7% lead, 93% follow
Portfolio highlights
- Synthesize Bio — AI-powered gene expression models predict human tissue responses to drugs. De-risk clinical trials, optimize patient selection, and accelerate drug development.
- Archon Biosciences — Archon is a biotechnology firm that creates computationally engineered proteins to unleash potent therapeutic targets beyond the grasp of current methods and improve disease management.
- ZymeCO — ZymeCO is a bio-manufacturing company that develops enzyme-based biological products designed for sustainable agriculture and turf management. The company utilizes a bio-process that transforms organic matter to build soil health, accelerate residue decomposition, and boost plant growth.
Engineering solutions to complex problems in health through venture investment and company creation.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Seed, Series B
- Geography: United States, United Kingdom, China
Investor stats
- Total investments: 120
- Round size: Seed $1.5M–$15M; Series A $7.5M–$66M; Series B $13M–$150M
- Lead/follow: 16% lead, 84% follow
- Last fund: Likely still investing — raised $300M in 2023
Portfolio highlights
- Sparkle Grooming Co. — Sparkle is a national wellness-focused dog grooming franchise and pioneer of Quick Service Pet Care (QSPC), a modern approach to routine pet care that combines membership-based services, technology-enabled operations, and a premium salon experience. The company provides recurring grooming and wellness services designed to keep dogs clean, healthy,and happy while helping franchise partners build scalable pet care businesses across the country.
- Enveda Biosciences — Enveda exists to give hope to millions of people around the world by accelerating the discovery of better medicines.
- Matchpoint Therapeutics — Matchpoint aims to discover and develop precision small molecules that harness the power of covalency to bring new possibilities to the treatment of serious immune disease and cancer.
SR One Capital Management is a leading trans-Atlantic biotech venture capital firm that partners with top entrepreneurs, scientists and investment partners to seek to build elite biotechnology companies. Our mission is to translate ground-breaking technologies into next generation medicines to benef
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Series B, Series C
- Geography: United States, United Kingdom, Canada
Investor stats
- Total investments: 203
- Round size: Series A $6M–$100M; Series B $15M–$114M; Series C $22M–$175M
- Lead/follow: 33% lead, 67% follow
- Last fund: Likely actively investing — fresh fund, raised $237M in 2025
Portfolio highlights
- CalciMedica — CalciMedica is a clinical-stage biopharmaceutical company advancing CRAC channel inhibitors for pulmonary hypertension and acute pancreatitis.
- Windward Bio — Windward Bio is a clinical-stage, drug development company committed to improving outcomes for people living with serious immunological diseases.
- Korsana Biosciences — Korsana Biosciences develops THETA-enabled antibody therapies for neurodegenerative diseases. The company focuses on shuttled monoclonal antibodies that cross the blood-brain barrier to reach central nervous system targets. Its lead program, KRSA-028, is an investigational anti-amyloid beta antibody for Alzheimer’s disease that uses a transferrinreceptor-based shuttle and Fc engineering to improve brain delivery and dosing. Korsana is also advancing additional THETA-based programs for undisclosed neurodegenerative indications.
The firm is a 25-year-old global investment firm focused on healthcare with approximately $5.8 billion in AUM, which we have invested in over 290 public and private companies worldwide. Headquartered in Palo Alto, California, with offices in Asia. Our team consists of 50 multi-disciplinary professionals, including, physicians, scientists,entrepreneurs, operating executives, and industry experts. The firm operates as a multi-fund investment platform, covering growth equity, private equity including buyout, venture capital, and public equity. Vivo invests broadly in healthcare across all fund strategies, including biotechnology, pharmaceuticals, medical devices, and healthcare services, with a focus on the largest healthcare markets.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Pharmaceutical
- Stage:Post-IPO Equity, Series B, Series C
- Geography: United States, China, United Kingdom
Investor stats
- Total investments: 265
- Round size: Series B $28M–$137M; Series C $30M–$142M; Post-IPO Equity $35M–$180M
- Lead/follow: 27% lead, 73% follow
- Last fund: Likely actively investing — fresh fund, raised $740M in 2025
Portfolio highlights
- Serán Bioscience — Leading pharmaceutical innovator offering tailored drug solutions with comprehensive analytical and manufacturing services for biotech and pharma.
- Korsana Biosciences — Korsana Biosciences develops THETA-enabled antibody therapies for neurodegenerative diseases. The company focuses on shuttled monoclonal antibodies that cross the blood-brain barrier to reach central nervous system targets. Its lead program, KRSA-028, is an investigational anti-amyloid beta antibody for Alzheimer’s disease that uses a transferrinreceptor-based shuttle and Fc engineering to improve brain delivery and dosing. Korsana is also advancing additional THETA-based programs for undisclosed neurodegenerative indications.
- Expedition Therapeutics — Redefining Care. Advancing COPD and Other Respiratory Therapies. Expedition Therapeutics is developing novel treatments for inflammatory and respiratory diseases with the potential to fundamentally transform patient care worldwide. ABOUT US At Expedition Therapeutics, we believe that disease-controlling treatments that address fundamental disease mechanisms should be the new standard for chronic obstructive pulmonary disease (COPD). Our
Life Science Investor funding in United States at a glance
Stats across 4.1k deals from 4.1k investors.
Access all 4079 investors in United States Life Science startups.
Open ListFAQ
Is Shizune data fresh/accurate?
Shizune has monitored hundreds of funding sources since 2020.
Our investor database is updated every day, so investor data is always fresh.
All metrics are calculated from confirmed public rounds, so the data is accurate.
Can I download investor list?
To download the Life Science Investors in United States investor list, create a Shizune account. This investor list will be added to your saved investors and available for download in the export section.
You can also enrich the investor list with investor emails, phones, LinkedIns, and other contact data.
Can I access investor database?
To access all 4079 investors investing in United States Life Science startups and 48,091+ more investors, create a Shizune account.
Shizune has a database of 48,091 investors. Our investor database is fresh and updated daily.
The Shizune investor database has information on investor investment focus, investor contact data, and full investor portfolio since 2020.
You can enrich with email and download the data.
Does Shizune have investor emails and contacts?
Shizune enriches investors with contact data that includes: email, phones, LinkedIn, socials, website, and others.
To guarantee the highest discovery rate, we search across 20+ contact search tools.
To maximize delivery rate and reduce bounce rate, we validate emails.
You can enrich your investor list with Shizune. Download it too.
What is Shizune?
Shizune is a 48,091 investor database updated daily.
With Shizune you can:
- browse the database
- use smart matching
- enrich with emails
- download
All you need to find investors for your startup.
Who is Shizune for?
Shizune is built for startup founders by startup founders.
If you are looking for funding for your startup, try the Shizune database — we have investors for every stage, industry, and country.
Is Shizune free?
Shizune is free forever. You can search and browse investors for free.
Email search and export are paid features.
For full info, visit our pricing.
Who built Shizune?
Shizune is built by founders with the goal of helping all founders raise funding no matter where they are.
Contact 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!